The Fly | DCOY

Novel Mechanism of Action: Seclidemstat targets the menin-MLL pathway, representing a unique epigenetic approach to treating certain cancers, which may offer advantages over existing therapies.

Focus on High Unmet Needs: The company primarily targets rare and difficult-to-treat cancers like Ewing sarcoma and AML, where current treatment options are limited, offering a significant market opportunity.

Orphan Drug Designations Secured: Multiple orphan drug designations for seclidemstat provide benefits such as extended market exclusivity, tax credits, and reduced regulatory fees, streamlining development and commercialization.

Clinical Trial Failure Risk: The company's drug candidates may not achieve positive results in ongoing or future clinical trials, leading to a halt in development and potential asset impairment.

Regulatory Approval Uncertainty Risk: Salarius Pharmaceuticals may not be able to obtain the necessary regulatory approvals from health authorities, such as the FDA, for its drug candidates.

Significant Capital Needs Risk: The company will require substantial additional financing to fund its operations and complete its clinical development programs, and there is no guarantee such funding will be available on acceptable terms.

Novel Mechanism of Action: Seclidemstat targets the menin-MLL pathway, representing a unique epigenetic approach to treating certain cancers, which may offer advantages over existing therapies.

Clinical Trial Failure Risk: The company's drug candidates may not achieve positive results in ongoing or future clinical trials, leading to a halt in development and potential asset impairment.

Regulatory Approval Uncertainty Risk: Salarius Pharmaceuticals may not be able to obtain the necessary regulatory approvals from health authorities, such as the FDA, for its drug candidates.